Identification of novel MDR antimicrobials from human microbiome symbioses

从人类微生物组共生体中鉴定新型耐多药抗菌药物

• 批准号: 10592388
• 负责人: NASIA SAFDAR
• 金额: $ 126.61万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10592388
• 关键词: Identification; novel; MDR; antimicrobials; human

Project 3 Project Summary The human body is host to, and interacts with, a complex and dynamic community of microbes called the microbiome. One critical function of the human microbiome is to help protect its host from infection. In project three, we will identify members of the microbiome that can produce antibiotics that are active against drug resistant pathogens and safe for human use. Through the use of genomics, we predict that the human microbiome has the capacity to produce thousands of bioactive natural products that have not been characterized. At UW-Madison, we have several large and ongoing human microbiome studies that provide us access to thousands of samples from diverse populations of people for the isolation and screening of new antimicrobial molecules. We will isolate microbes derived from the human microbiome, determine their antimicrobial activity against Gram-negative and fungal pathogens, and apply our genomics and metabolomics approaches to predict molecules with new chemistry. Our project goals contribute to the mission of the Wisconsin Antimicrobial Drug Discovery and Development Center aiming to develop new therapeutics in response to the growing antimicrobial resistance crisis.

项目3 项目摘要 人体是托管的，并与一个复杂而动态的微生物社区互动称为 微生物组。人类微生物组的一个关键功能是帮助保护其宿主免受感染。在 第三项目，我们将确定可产生活跃抗生素的微生物组成员 抗药病原体，可用于人类使用。通过使用基因组学，我们预测 人类微生物组有能力生产具有数千种具有的生物活性天然产品 没有被描述。在UW-Madison，我们进行了一些大型且正在进行的人类微生物组研究 这为我们提供了来自不同人群的数千个样本进行隔离和 筛选新的抗菌分子。我们将分离源自人类微生物组的微生物， 确定其针对革兰氏阴性和真菌病原体的抗菌活性，并应用我们 基因组学和代谢组学方法可预测新化学的分子。我们的项目目标 促进威斯康星州抗菌药物发现与开发中心的任务 为了应对日益增长的抗菌素耐药性危机，开发新的治疗剂。